Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ropinirole prolonged release · 1 trial · 1 indication
Diary cards completed by the participants was used to assess the duration of "off" and "on" periods. During the treatment period 2, 24 hour diary cards were completed by the participants (except for the Baseline period when four diary cards were completed). The participants completed diary cards on the same 2 days of each relevant week. Each 30 minute period was marked as either "off", "on" or asleep. Troublesome dyskinesias were involuntary twisting, turning movements which caused discomfort were also recorded. The general definition of "off" included a lack of mobility with or without additional features such as tremor or rigidity. The total number of hours spent both "off" and "on" or asleep were summed for the two (four for the Baseline Period) 24 hour diary cards and the amount of awake time spent "off" per 24 hour period was determined. Percentage of participants with at least a 20% maintained reduction in baseline time spent "off" at Week 24 were presented.
| Name | Type | Description |
|---|---|---|
| Ropinirole prolonged release | DRUG | - |
| ropinirole immediate release | DRUG | - |
Inclusion criteria: * Patients with a diagnosis of advanced idiopathic Parkinson's disease (according to modified Hoehn \& Yahr criteria Stages II-IV) whose symptoms are not adequately controlled with L-dopa. Exclusion criteria: * Patients with late stage advanced Parkinson's disease with incapac...
Ropinirole prolonged release is used for Parkinson Disease. It is a small molecule being developed by GSK plc (GSK) for this neurological condition. The drug is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved for use.
Ropinirole prolonged release is a small molecule developed for Parkinson Disease. The specific molecular target has not been disclosed in the available information, so its mechanism of action is not described here.
Ropinirole prolonged release is developed by GSK plc, a pharmaceutical company traded under the ticker GSK. The drug is being studied for the treatment of Parkinson Disease and is currently in Phase 3 clinical trials.
Ropinirole prolonged release is in Phase 3 clinical development for Parkinson Disease. It is an investigational drug, meaning it has not been approved by regulatory authorities. One Phase 3 trial has been completed, involving 343 patients.
Ropinirole prolonged release has one completed Phase 3 trial, NCT00331149, titled 'A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's'. The trial enrolled 343 patients across multiple countries including Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Romania, Russia, South Africa, Spain, Ukraine, and the United Kingdom.
Ropinirole prolonged release is a distinct formulation from Ropinirole immediate release. The completed clinical trial NCT00331149 directly compared the two formulations in patients with advanced Parkinson's Disease, indicating they are separate versions of the same active ingredient with different release profiles.